Application of silicified microcrystalline cellulose (Prosolv) as a polymer carrier of Epilobium parviflorum Schreb. extract in oral solid drug form.
Direct tableting is simpler and more cost-effective from the point of view of good manufacturing practice (GMP) than wet granulation or dry compacting. Thus, pharmaceutical industry more and more frequently uses this particular process. Only few therapeutic substances form under compression tablets meeting current requirements. Very often additional adjuvants must be used. These substances have the ability of increasing plastic deformation and tablet mass liquidity. Microcrystalline cellulose belongs to the best adjuvant substances of the type. It has binding, disintegrating and improving liquidity properties. This study aims at investigating the usefulness of selected high-molecular substances with particular consideration of silici-fled microcrystalline cellulose (Prosolv) and croscarmellose sodium (Vivasol) as a carrier of E. parviflorum Schreb. extract in oral solid drug form in the process of direct tab-leting. The manufactured tablets were subjected to morphological tests and pharmaceutical availability tests of biologically active substances from a tablet to the acceptor fluid. The investigations were based on general and detailed principles of Polish Pharmacopoeia VI. The obtained results allow to state that the applied high-molecular adjuvant substances proved to be useful in adequate proportions in the production of tablets from dry extract from Epilobium parviflo-rum Schreb. Generally, a significant shortening of the tablets disintegration time was obtained as compared to earlier produced tablets with the method of initial granulation. The tablets formed from E. parviflorum Schreb. extract with silicified microcrystalline cellulose (Prosolv SMCC 50) and croscarmellose sodium can be included into preparations of short dissolution time of the therapeutic substance.
Marczyński
Zbigniew
Z
Department of Applied Pharmacy, Medical University of Lodz.
Zgoda
Marian Mikołaj
MM
Jambor
Jerzy
J
D000284:Administration, Oral; D001682:Biological Availability; D002482:Cellulose / Q000008:administration & dosage / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D031666:Epilobium / Q000737:chemistry*; D005079:Excipients / Q000737:chemistry; D004364:Pharmaceutical Preparations; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D012822:Silicon Dioxide / Q000737:chemistry*; D012995:Solubility / Q000187:drug effects; D013607:Tablets / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods
D004337:Drug Carriers; D005079:Excipients; D004364:Pharmaceutical Preparations; D010936:Plant Extracts; D011108:Polymers; D013607:Tablets; D012822:Silicon Dioxide; D002482:Cellulose; C109691:microcrystalline cellulose